IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
about
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patientsSerum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trialInducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Current and future therapies for hepatitis C virus infection.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patientsTryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis CHigh MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activityAssociation of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis CThe Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.Individualization of chronic hepatitis C treatment according to the host characteristics.Current understanding of insulin resistance in hepatitis C.A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.Genetics of IL28B and HCV--response to infection and treatment.Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.CXC chemokine IP-10: a key actor in liver disease?Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients.Valine, a branched-chain amino Acid, reduced HCV viral load and led to eradication of HCV by interferon therapy in a decompensated cirrhotic patient.Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response.Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
P2860
Q28539645-FFC02947-E2DA-4CEB-9B7A-8C20CDE0819CQ29417108-9ECD5B6F-0359-4A4F-A2D5-8245B2356E21Q33365130-AE299B19-6822-4E1B-ADDD-3BF1C814CCC6Q33706737-A03E27B5-009B-4F38-94EF-9F7D77E9F55FQ33745372-05F26780-1844-4A2F-A13B-3EEB7DE70E0AQ34036762-1CF6EAD1-95E3-4349-9E0E-E88FF918423CQ34429833-1EEC2EBF-A39D-420A-BBD8-0E2DA05A2713Q34539324-68AB32EC-7F4D-44A9-B77A-0BCBB7B52B6EQ34744383-6A9B17A0-A5A5-411C-B4C7-ADE49A3902B2Q34769512-68DEF14A-2291-407F-BCFF-605BE34B08A4Q34981566-C418D2B5-473E-4948-AEF9-865775B8762AQ35818383-A88911AF-6F6C-4312-B3AA-2893355B347EQ36208380-B91DF455-0ADC-416E-9AA7-6101D363670DQ36554751-BAA05DA2-F3FD-438B-AA2C-B4E404AB1D37Q36848968-7AA61C2E-9419-41BE-8023-D63B1378D740Q36996953-7279BABF-3A9F-412D-B73C-D702DD9FC099Q37309030-2948422F-CF7D-437E-A5F5-0FC31467DC1AQ37639317-85D5926D-72E0-45C4-A4EC-490B131BD47CQ37654502-7203AE79-EF51-499C-B35F-C173684C1524Q37903853-4FDB8D58-0F35-4FF8-B2FE-7E16FFA3D294Q37992195-AF6C9FD2-7D91-4519-B2A6-71403DF4B5FDQ38011758-72BE2CE7-D0F5-4B5B-9EC8-CDFA3F005ABFQ38013941-65E7229F-E37C-4F51-A9AB-806E8DDE6506Q38136078-21CED58D-DE79-497D-9823-F16D632E9D85Q38174868-96978EFE-D8E7-4904-90B5-E5B0C8C44FD8Q38249236-2A6FE9A6-0F40-4D52-998C-3000451B6EF1Q38445623-B692CFEA-FF9E-478C-8B03-7FD0DC4974D0Q38477511-8885A90C-E03B-4DDC-88F0-6D2B6981B061Q38552265-94AE5496-A74D-4E03-8B0B-5DF12A3B53B0Q41723912-9FEAF213-7F7D-40F1-B802-57924E0E971FQ41872592-2FBA714F-75DC-4805-826B-04CEA712EE9FQ42180401-C3C89569-816D-46D8-BCFB-8363B867D9C3Q42223349-9E835C11-100A-4C99-BC1E-3A38379C9F5EQ42234969-7D74E183-153A-46D6-ABA9-D0FC216059CDQ42245782-63F7943D-1AF8-4C40-8475-9DDD2D7AE8BAQ42250948-933FF0ED-87C9-4B57-89C5-3EB83E04E509Q42263066-885C5958-D190-4984-8B9F-A4F1845895BEQ42913315-16F4ECA4-2CE6-4678-A445-E4AF78D405C3Q42977737-FE698BF0-FD9B-4EFF-A5AF-9237FFE34539Q42980531-68601CEA-E450-4EC0-9EEA-63CE0CF9F142
P2860
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@en
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@nl
type
label
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@en
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@nl
prefLabel
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@en
IL28B polymorphisms, IP-10 and ...... herapy in chronic hepatitis C.
@nl
P2093
P2860
P50
P1476
IL28B polymorphisms, IP-10 and ...... therapy in chronic hepatitis C
@en
P2093
G Askarieh
G Fattovich
G Raimondo
ITAHEC Study Group
P2860
P304
P356
10.1111/J.1365-2036.2011.04635.X
P407
P577
2011-03-28T00:00:00Z